The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 05, 2022
Filed:
Sep. 24, 2019
Applicant:
Array Biopharma Inc., Boulder, CO (US);
Inventors:
Giordano Caponigro, Cambridge, MA (US);
Zhu Alexander Cao, Cambridge, MA (US);
Assignee:
ARRAY BIOPHARMA INC, Boulder, CO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 31/506 (2006.01); A61K 39/395 (2006.01); A61P 35/04 (2006.01); A61K 45/06 (2006.01); A61K 31/573 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/506 (2013.01); A61K 31/573 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2863 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract
Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.